GSA Capital Partners LLP lifted its position in shares of Amarin Co. plc (NASDAQ:AMRN) by 66.3% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 162,800 shares of the biopharmaceutical company’s stock after purchasing an additional 64,900 shares during the period. GSA Capital Partners LLP owned about 0.06% of Amarin worth $503,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. DRW Securities LLC increased its position in shares of Amarin by 45.1% during the first quarter. DRW Securities LLC now owns 80,400 shares of the biopharmaceutical company’s stock worth $242,000 after purchasing an additional 25,000 shares in the last quarter. Private Advisor Group LLC increased its position in shares of Amarin by 81.8% during the first quarter. Private Advisor Group LLC now owns 64,293 shares of the biopharmaceutical company’s stock worth $194,000 after purchasing an additional 28,929 shares in the last quarter. TD Asset Management Inc. increased its position in shares of Amarin by 54.4% during the second quarter. TD Asset Management Inc. now owns 134,207 shares of the biopharmaceutical company’s stock worth $415,000 after purchasing an additional 47,300 shares in the last quarter. Rock Springs Capital Management LP increased its position in shares of Amarin by 1.3% during the first quarter. Rock Springs Capital Management LP now owns 4,000,000 shares of the biopharmaceutical company’s stock worth $12,040,000 after purchasing an additional 50,000 shares in the last quarter. Finally, Claraphi Advisory Network LLC increased its position in shares of Amarin by 637.3% during the first quarter. Claraphi Advisory Network LLC now owns 85,309 shares of the biopharmaceutical company’s stock worth $257,000 after purchasing an additional 73,738 shares in the last quarter. Institutional investors and hedge funds own 38.28% of the company’s stock.

AMRN opened at $2.83 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.43 and a debt-to-equity ratio of -1.25. Amarin Co. plc has a one year low of $2.35 and a one year high of $4.60.

Amarin (NASDAQ:AMRN) last released its quarterly earnings results on Wednesday, August 1st. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.09) by ($0.03). The company had revenue of $52.64 million during the quarter, compared to analysts’ expectations of $54.88 million. During the same quarter in the prior year, the company posted ($0.04) earnings per share. The firm’s revenue was up 16.4% on a year-over-year basis. research analysts expect that Amarin Co. plc will post -0.42 earnings per share for the current year.

In related news, General Counsel Joseph T. Kennedy sold 26,942 shares of the firm’s stock in a transaction dated Monday, July 2nd. The stock was sold at an average price of $3.00, for a total transaction of $80,826.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 4.08% of the company’s stock.

AMRN has been the topic of a number of research analyst reports. Cantor Fitzgerald set a $10.00 target price on Amarin and gave the stock a “buy” rating in a research report on Wednesday, August 1st. BidaskClub upgraded Amarin from a “hold” rating to a “buy” rating in a research report on Monday, June 18th. Finally, ValuEngine upgraded Amarin from a “hold” rating to a “buy” rating in a research report on Thursday, May 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $8.00.

About Amarin

Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.

Further Reading: Risk Tolerance and Your Investment Decisions

Institutional Ownership by Quarter for Amarin (NASDAQ:AMRN)

Receive News & Ratings for Amarin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin and related companies with MarketBeat.com's FREE daily email newsletter.